“It’s like ‘liquid handcuffs”: The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients’ lives

Methadone Maintenance Treatment (MMT) is widely recognized as one of the most effective ways of reducing risk of overdose, arrest, and transmission of blood-borne viruses like HIV and HCV among people that use opioids. Yet, MMT's use of restrictive take-home dose policies that force most patien...

Full description

Saved in:
Bibliographic Details
Published inHarm reduction journal Vol. 18; no. 1; pp. 88 - 10
Main Authors Frank, David, Mateu-Gelabert, Pedro, Perlman, David C., Walters, Suzan M., Curran, Laura, Guarino, Honoria
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 14.08.2021
BioMed Central
BMC
Subjects
Clinics
Coronaviruses
COVID-19
Disease transmission
Dosage
Drug dosages
Drug use
Harm reduction
HIV
Human immunodeficiency virus
Humans
Maintenance
Marginalized groups
Medical research
Methadone
Methadone - therapeutic use
Methadone clinics
Methadone maintenance
Methadone Maintenance Treatment (MMT)
Methods
Narcotics
Opiate Substitution Treatment
Opioid-Related Disorders - drug therapy
Opioids
Overdose
Patient outcomes
Patient satisfaction
Patients
Patients’ rights
Policies
Policy
Public health
Retention
Risk management
Risk reduction
Stigma
Substance use
Take-home doses
Trauma
United States
United States > US
New York City New York
Harm reduction
Methadone Maintenance Treatment (MMT)
Patients’ rights
Methadone clinics
Stigma
Take-home doses
Online AccessGet full text

Cover

Abstract Methadone Maintenance Treatment (MMT) is widely recognized as one of the most effective ways of reducing risk of overdose, arrest, and transmission of blood-borne viruses like HIV and HCV among people that use opioids. Yet, MMT's use of restrictive take-home dose policies that force most patients to attend their clinic on a daily, or near-daily, basis may be unpopular with many patients and lead to low rates of treatment uptake and retention. In response, this article examines how clinics' take-home dosing policies have affected patients' experiences of treatment and lives in general. This article is based on semi-structured, qualitative interviews with a variety of stakeholders in MMT. Interviews explored: reasons for engaging with, or not engaging with MMT; how MMT is conceptualized by patients and treatment providers (e.g., as harm reduction or route to abstinence and/or recovery); experiences with MMT; perception of barriers to MMT (e.g., organizational/regulatory, social) and how MMT might be improved to support peoples' substance use treatment needs and goals. Nearly all of the patients with past or present MMT use were highly critical of the limited access to take-home doses and consequent need for daily or near daily clinic attendance. Participants described how the use of restrictive take-home dose policies negatively impacted their ability to meet day-to-day responsibilities and also cited the need for daily attendance as a reason for quitting or avoiding OAT. Responses also demonstrate how such policies contribute to an environment of cruelty and stigma within many clinics that exposes this already-stigmatized population to additional trauma. Take-home dose policies in MMT are not working for a substantial number of patients and are reasonably seen by participants as degrading and dehumanizing. Revision of MMT regulations and policies regarding take home doses are essential to improve patient satisfaction and the quality and effectiveness of MMT as a key evidence-based treatment and harm reduction strategy.
AbstractList Abstract Background Methadone Maintenance Treatment (MMT) is widely recognized as one of the most effective ways of reducing risk of overdose, arrest, and transmission of blood-borne viruses like HIV and HCV among people that use opioids. Yet, MMT’s use of restrictive take-home dose policies that force most patients to attend their clinic on a daily, or near-daily, basis may be unpopular with many patients and lead to low rates of treatment uptake and retention. In response, this article examines how clinics’ take-home dosing policies have affected patients’ experiences of treatment and lives in general. Methods This article is based on semi-structured, qualitative interviews with a variety of stakeholders in MMT. Interviews explored: reasons for engaging with, or not engaging with MMT; how MMT is conceptualized by patients and treatment providers (e.g., as harm reduction or route to abstinence and/or recovery); experiences with MMT; perception of barriers to MMT (e.g., organizational/regulatory, social) and how MMT might be improved to support peoples’ substance use treatment needs and goals. Results Nearly all of the patients with past or present MMT use were highly critical of the limited access to take-home doses and consequent need for daily or near daily clinic attendance. Participants described how the use of restrictive take-home dose policies negatively impacted their ability to meet day-to-day responsibilities and also cited the need for daily attendance as a reason for quitting or avoiding OAT. Responses also demonstrate how such policies contribute to an environment of cruelty and stigma within many clinics that exposes this already-stigmatized population to additional trauma. Conclusions Take-home dose policies in MMT are not working for a substantial number of patients and are reasonably seen by participants as degrading and dehumanizing. Revision of MMT regulations and policies regarding take home doses are essential to improve patient satisfaction and the quality and effectiveness of MMT as a key evidence-based treatment and harm reduction strategy.
Methadone Maintenance Treatment (MMT) is widely recognized as one of the most effective ways of reducing risk of overdose, arrest, and transmission of blood-borne viruses like HIV and HCV among people that use opioids. Yet, MMT's use of restrictive take-home dose policies that force most patients to attend their clinic on a daily, or near-daily, basis may be unpopular with many patients and lead to low rates of treatment uptake and retention. In response, this article examines how clinics' take-home dosing policies have affected patients' experiences of treatment and lives in general. This article is based on semi-structured, qualitative interviews with a variety of stakeholders in MMT. Interviews explored: reasons for engaging with, or not engaging with MMT; how MMT is conceptualized by patients and treatment providers (e.g., as harm reduction or route to abstinence and/or recovery); experiences with MMT; perception of barriers to MMT (e.g., organizational/regulatory, social) and how MMT might be improved to support peoples' substance use treatment needs and goals. Nearly all of the patients with past or present MMT use were highly critical of the limited access to take-home doses and consequent need for daily or near daily clinic attendance. Participants described how the use of restrictive take-home dose policies negatively impacted their ability to meet day-to-day responsibilities and also cited the need for daily attendance as a reason for quitting or avoiding OAT. Responses also demonstrate how such policies contribute to an environment of cruelty and stigma within many clinics that exposes this already-stigmatized population to additional trauma. Take-home dose policies in MMT are not working for a substantial number of patients and are reasonably seen by participants as degrading and dehumanizing. Revision of MMT regulations and policies regarding take home doses are essential to improve patient satisfaction and the quality and effectiveness of MMT as a key evidence-based treatment and harm reduction strategy.
Methadone Maintenance Treatment (MMT) is widely recognized as one of the most effective ways of reducing risk of overdose, arrest, and transmission of blood-borne viruses like HIV and HCV among people that use opioids. Yet, MMT's use of restrictive take-home dose policies that force most patients to attend their clinic on a daily, or near-daily, basis may be unpopular with many patients and lead to low rates of treatment uptake and retention. In response, this article examines how clinics' take-home dosing policies have affected patients' experiences of treatment and lives in general.BACKGROUNDMethadone Maintenance Treatment (MMT) is widely recognized as one of the most effective ways of reducing risk of overdose, arrest, and transmission of blood-borne viruses like HIV and HCV among people that use opioids. Yet, MMT's use of restrictive take-home dose policies that force most patients to attend their clinic on a daily, or near-daily, basis may be unpopular with many patients and lead to low rates of treatment uptake and retention. In response, this article examines how clinics' take-home dosing policies have affected patients' experiences of treatment and lives in general.This article is based on semi-structured, qualitative interviews with a variety of stakeholders in MMT. Interviews explored: reasons for engaging with, or not engaging with MMT; how MMT is conceptualized by patients and treatment providers (e.g., as harm reduction or route to abstinence and/or recovery); experiences with MMT; perception of barriers to MMT (e.g., organizational/regulatory, social) and how MMT might be improved to support peoples' substance use treatment needs and goals.METHODSThis article is based on semi-structured, qualitative interviews with a variety of stakeholders in MMT. Interviews explored: reasons for engaging with, or not engaging with MMT; how MMT is conceptualized by patients and treatment providers (e.g., as harm reduction or route to abstinence and/or recovery); experiences with MMT; perception of barriers to MMT (e.g., organizational/regulatory, social) and how MMT might be improved to support peoples' substance use treatment needs and goals.Nearly all of the patients with past or present MMT use were highly critical of the limited access to take-home doses and consequent need for daily or near daily clinic attendance. Participants described how the use of restrictive take-home dose policies negatively impacted their ability to meet day-to-day responsibilities and also cited the need for daily attendance as a reason for quitting or avoiding OAT. Responses also demonstrate how such policies contribute to an environment of cruelty and stigma within many clinics that exposes this already-stigmatized population to additional trauma.RESULTSNearly all of the patients with past or present MMT use were highly critical of the limited access to take-home doses and consequent need for daily or near daily clinic attendance. Participants described how the use of restrictive take-home dose policies negatively impacted their ability to meet day-to-day responsibilities and also cited the need for daily attendance as a reason for quitting or avoiding OAT. Responses also demonstrate how such policies contribute to an environment of cruelty and stigma within many clinics that exposes this already-stigmatized population to additional trauma.Take-home dose policies in MMT are not working for a substantial number of patients and are reasonably seen by participants as degrading and dehumanizing. Revision of MMT regulations and policies regarding take home doses are essential to improve patient satisfaction and the quality and effectiveness of MMT as a key evidence-based treatment and harm reduction strategy.CONCLUSIONSTake-home dose policies in MMT are not working for a substantial number of patients and are reasonably seen by participants as degrading and dehumanizing. Revision of MMT regulations and policies regarding take home doses are essential to improve patient satisfaction and the quality and effectiveness of MMT as a key evidence-based treatment and harm reduction strategy.
Background Methadone Maintenance Treatment (MMT) is widely recognized as one of the most effective ways of reducing risk of overdose, arrest, and transmission of blood-borne viruses like HIV and HCV among people that use opioids. Yet, MMT's use of restrictive take-home dose policies that force most patients to attend their clinic on a daily, or near-daily, basis may be unpopular with many patients and lead to low rates of treatment uptake and retention. In response, this article examines how clinics' take-home dosing policies have affected patients' experiences of treatment and lives in general. Methods This article is based on semi-structured, qualitative interviews with a variety of stakeholders in MMT. Interviews explored: reasons for engaging with, or not engaging with MMT; how MMT is conceptualized by patients and treatment providers (e.g., as harm reduction or route to abstinence and/or recovery); experiences with MMT; perception of barriers to MMT (e.g., organizational/regulatory, social) and how MMT might be improved to support peoples' substance use treatment needs and goals. Results Nearly all of the patients with past or present MMT use were highly critical of the limited access to take-home doses and consequent need for daily or near daily clinic attendance. Participants described how the use of restrictive take-home dose policies negatively impacted their ability to meet day-to-day responsibilities and also cited the need for daily attendance as a reason for quitting or avoiding OAT. Responses also demonstrate how such policies contribute to an environment of cruelty and stigma within many clinics that exposes this already-stigmatized population to additional trauma. Conclusions Take-home dose policies in MMT are not working for a substantial number of patients and are reasonably seen by participants as degrading and dehumanizing. Revision of MMT regulations and policies regarding take home doses are essential to improve patient satisfaction and the quality and effectiveness of MMT as a key evidence-based treatment and harm reduction strategy. Keywords: Methadone Maintenance Treatment (MMT), Take-home doses, Methadone clinics, Harm reduction, Patients' rights, Stigma
Background Methadone Maintenance Treatment (MMT) is widely recognized as one of the most effective ways of reducing risk of overdose, arrest, and transmission of blood-borne viruses like HIV and HCV among people that use opioids. Yet, MMT’s use of restrictive take-home dose policies that force most patients to attend their clinic on a daily, or near-daily, basis may be unpopular with many patients and lead to low rates of treatment uptake and retention. In response, this article examines how clinics’ take-home dosing policies have affected patients’ experiences of treatment and lives in general. Methods This article is based on semi-structured, qualitative interviews with a variety of stakeholders in MMT. Interviews explored: reasons for engaging with, or not engaging with MMT; how MMT is conceptualized by patients and treatment providers (e.g., as harm reduction or route to abstinence and/or recovery); experiences with MMT; perception of barriers to MMT (e.g., organizational/regulatory, social) and how MMT might be improved to support peoples’ substance use treatment needs and goals. Results Nearly all of the patients with past or present MMT use were highly critical of the limited access to take-home doses and consequent need for daily or near daily clinic attendance. Participants described how the use of restrictive take-home dose policies negatively impacted their ability to meet day-to-day responsibilities and also cited the need for daily attendance as a reason for quitting or avoiding OAT. Responses also demonstrate how such policies contribute to an environment of cruelty and stigma within many clinics that exposes this already-stigmatized population to additional trauma. Conclusions Take-home dose policies in MMT are not working for a substantial number of patients and are reasonably seen by participants as degrading and dehumanizing. Revision of MMT regulations and policies regarding take home doses are essential to improve patient satisfaction and the quality and effectiveness of MMT as a key evidence-based treatment and harm reduction strategy.
Methadone Maintenance Treatment (MMT) is widely recognized as one of the most effective ways of reducing risk of overdose, arrest, and transmission of blood-borne viruses like HIV and HCV among people that use opioids. Yet, MMT's use of restrictive take-home dose policies that force most patients to attend their clinic on a daily, or near-daily, basis may be unpopular with many patients and lead to low rates of treatment uptake and retention. In response, this article examines how clinics' take-home dosing policies have affected patients' experiences of treatment and lives in general. This article is based on semi-structured, qualitative interviews with a variety of stakeholders in MMT. Interviews explored: reasons for engaging with, or not engaging with MMT; how MMT is conceptualized by patients and treatment providers (e.g., as harm reduction or route to abstinence and/or recovery); experiences with MMT; perception of barriers to MMT (e.g., organizational/regulatory, social) and how MMT might be improved to support peoples' substance use treatment needs and goals. Nearly all of the patients with past or present MMT use were highly critical of the limited access to take-home doses and consequent need for daily or near daily clinic attendance. Participants described how the use of restrictive take-home dose policies negatively impacted their ability to meet day-to-day responsibilities and also cited the need for daily attendance as a reason for quitting or avoiding OAT. Responses also demonstrate how such policies contribute to an environment of cruelty and stigma within many clinics that exposes this already-stigmatized population to additional trauma. Take-home dose policies in MMT are not working for a substantial number of patients and are reasonably seen by participants as degrading and dehumanizing. Revision of MMT regulations and policies regarding take home doses are essential to improve patient satisfaction and the quality and effectiveness of MMT as a key evidence-based treatment and harm reduction strategy.
ArticleNumber 88
Audience Academic
Author Mateu-Gelabert, Pedro
Frank, David
Curran, Laura
Walters, Suzan M.
Guarino, Honoria
Perlman, David C.
Author_xml – sequence: 1
  givenname: David
  orcidid: 0000-0003-3304-3237
  surname: Frank
  fullname: Frank, David
– sequence: 2
  givenname: Pedro
  surname: Mateu-Gelabert
  fullname: Mateu-Gelabert, Pedro
– sequence: 3
  givenname: David C.
  surname: Perlman
  fullname: Perlman, David C.
– sequence: 4
  givenname: Suzan M.
  surname: Walters
  fullname: Walters, Suzan M.
– sequence: 5
  givenname: Laura
  surname: Curran
  fullname: Curran, Laura
– sequence: 6
  givenname: Honoria
  surname: Guarino
  fullname: Guarino, Honoria
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34391436$$D View this record in MEDLINE/PubMed
BookMark eNp9kstuEzEYhUeoiF7gBVggS2zKYoovY88MC6Sq4hKpEZuwtjz2P4nTGTsdz1TKLmuegErwcnkSnKRUSYWQF759_7GPfU6TI-cdJMlrgi8IKcT7QGjJsxRTkmLMGU-Xz5ITkuV5mnOSH-2Nj5PTEOYYR54VL5JjlrGSZEycJD_Wq1-jfr26D6ixN4DWq5-NvR2sQTPljB7qOqxXvz-gyQwQ1DXoPiBfo17dQDrzLSDjg3VTtPCN1RbipkNj6GfKxLuisbKuB6ecBjTpQPUtuB6dj8eTd2ihehtnUf4-Hn0H4WXyvFZNgFcP_Vny_fOnydXX9Prbl9HV5XWquWB9yqGoqQGgpdBQGcA4mqG0yinFVFQFLUxJmRbC5JnAwIFnGcc1w0VZ6UpjdpaMdrrGq7lcdLZV3VJ6ZeV2wXdTqbre6gZkiXNijGKY1GWGuVAFFwZjgWlVMMNV1Pq401oMVQtGR0Odag5ED3ecncmpv5MFExnDeRQ4fxDo_O0AoZetDRqaRjnwQ5CUC1JSTAoS0bdP0LkfOhefakNRwVgu9qipigasq308V29E5aXIKcNZudW6-AcVm4HW6vh1tY3rBwVv9o0-OvybpAjQHaA7H0IH9SNCsNzEVe7iKmNc5TauchmLiidF2vYxF37zWLb5X-kfWWTyHQ
CitedBy_id crossref_primary_10_1002_jhm_13138
crossref_primary_10_1016_j_focus_2023_100102
crossref_primary_10_1016_j_jadohealth_2022_08_026
crossref_primary_10_1016_j_josat_2022_208946
crossref_primary_10_1200_JCO_24_00705
crossref_primary_10_1177_29767342241288981
crossref_primary_10_1097_jnr_0000000000000619
crossref_primary_10_1016_j_socscimed_2024_116683
crossref_primary_10_1016_j_josat_2023_209086
crossref_primary_10_1080_00952990_2023_2222336
crossref_primary_10_1016_j_forsciint_2023_111579
crossref_primary_10_1177_00220426241269828
crossref_primary_10_1016_j_drugpo_2023_104032
crossref_primary_10_1016_j_jsat_2022_108801
crossref_primary_10_1186_s13722_022_00303_8
crossref_primary_10_1016_j_focus_2023_100177
crossref_primary_10_1080_01459740_2022_2133706
crossref_primary_10_1016_j_socscimed_2024_116708
crossref_primary_10_1016_j_dadr_2022_100052
crossref_primary_10_1186_s12954_023_00896_6
crossref_primary_10_1016_j_josat_2024_209491
crossref_primary_10_3389_fpubh_2023_1201967
crossref_primary_10_1016_j_drugalcdep_2022_109459
crossref_primary_10_1016_j_drugpo_2024_104425
crossref_primary_10_1016_j_drugpo_2024_104420
crossref_primary_10_1186_s12954_023_00785_y
crossref_primary_10_1016_j_drugalcdep_2023_111036
crossref_primary_10_1136_bmj_2022_071467
crossref_primary_10_1080_16066359_2023_2292593
crossref_primary_10_1177_29767342241255480
crossref_primary_10_2196_69829
crossref_primary_10_1007_s11606_022_07817_6
crossref_primary_10_1080_09687637_2022_2102461
crossref_primary_10_1016_j_josat_2024_209538
crossref_primary_10_1186_s12954_022_00623_7
crossref_primary_10_1007_s11606_022_07939_x
crossref_primary_10_1186_s12954_025_01179_y
crossref_primary_10_3390_ijerph20054455
crossref_primary_10_1016_S2468_2667_23_00023_3
crossref_primary_10_1186_s12954_024_01029_3
crossref_primary_10_1186_s13722_024_00458_6
crossref_primary_10_3390_pharmaceutics14020461
crossref_primary_10_1016_j_tranpol_2024_08_001
crossref_primary_10_1016_j_drugalcdep_2023_109893
crossref_primary_10_1186_s12954_023_00893_9
crossref_primary_10_1016_j_drugpo_2025_104749
crossref_primary_10_1080_10428232_2025_2459993
crossref_primary_10_1016_j_ajem_2024_12_059
crossref_primary_10_1016_j_drugpo_2025_104746
crossref_primary_10_1136_bmjopen_2024_095198
crossref_primary_10_1016_j_drugpo_2023_104141
crossref_primary_10_1097_HJH_0000000000003840
crossref_primary_10_1111_add_70008
crossref_primary_10_1001_jamanetworkopen_2024_51988
crossref_primary_10_1111_add_16160
crossref_primary_10_1177_29767342251324325
crossref_primary_10_1093_aje_kwac217
crossref_primary_10_1016_j_josat_2023_209160
crossref_primary_10_1016_j_drugalcdep_2022_109703
crossref_primary_10_1016_j_hsr_2024_100195
crossref_primary_10_62401_2531_4122_2024_19
crossref_primary_10_1002_jhm_13329
crossref_primary_10_1080_10550887_2023_2212544
crossref_primary_10_1016_j_drugpo_2023_104075
crossref_primary_10_1016_j_drugalcdep_2022_109497
crossref_primary_10_1080_10550887_2023_2237394
crossref_primary_10_1001_jama_2022_1271
crossref_primary_10_1016_j_ssmqr_2023_100298
crossref_primary_10_1016_j_drugpo_2023_104123
crossref_primary_10_1016_j_drugpo_2024_104343
crossref_primary_10_1186_s12954_025_01165_4
crossref_primary_10_1016_j_drugpo_2023_104120
crossref_primary_10_2139_ssrn_4144150
crossref_primary_10_1016_j_josat_2024_209616
crossref_primary_10_1016_j_jsat_2022_108896
crossref_primary_10_3390_ijerph20021526
crossref_primary_10_1186_s13722_023_00402_0
crossref_primary_10_1186_s12954_022_00671_z
crossref_primary_10_1080_00952990_2024_2360984
crossref_primary_10_1371_journal_pone_0286859
crossref_primary_10_1186_s13011_023_00525_2
crossref_primary_10_1016_j_drugpo_2022_103768
crossref_primary_10_1016_j_drugpo_2022_103644
crossref_primary_10_1136_bmjopen_2022_068729
crossref_primary_10_1177_00914509241310745
crossref_primary_10_1186_s13722_024_00501_6
crossref_primary_10_2147_SAR_S484831
crossref_primary_10_1016_j_drugpo_2023_104058
crossref_primary_10_1186_s12913_023_09959_7
crossref_primary_10_12688_hrbopenres_14044_1
crossref_primary_10_1016_j_drugpo_2022_103752
crossref_primary_10_1002_jmv_29784
crossref_primary_10_1016_j_drugpo_2021_103573
crossref_primary_10_1186_s12913_023_09558_6
crossref_primary_10_1186_s12954_024_01008_8
crossref_primary_10_1016_j_josat_2023_209055
crossref_primary_10_1080_10826084_2022_2064509
crossref_primary_10_1016_j_drugpo_2024_104487
crossref_primary_10_1186_s13012_023_01281_4
crossref_primary_10_5694_mja2_52628
crossref_primary_10_1080_00909882_2023_2180770
crossref_primary_10_1371_journal_pone_0283979
Cites_doi 10.1111/j.1521-0391.2012.12004.x
10.15585/mmwr.mm6634a3
10.1080/10826084.2017.1310247
10.3389/fpsyg.2019.01052
10.1016/j.jsat.2020.108074
10.1023/A:1005574918294
10.11648/j.ajtas.20160501.11
10.3109/16066359808993303
10.4135/9781849208574.n4
10.1016/j.colegn.2018.01.002
10.1097/ADM.0b013e3182584772
10.1016/j.drugpo.2008.10.005
10.1097/ADM.0000000000000685
10.1016/j.jsat.2018.07.006
10.1016/j.jsat.2021.108449
10.15585/mmwr.mm6643e1
10.1016/j.drugpo.2020.102844
10.1080/10826084.2018.1555597
10.2105/AJPH.2012.301049
10.5617/jea.6737
10.1371/journal.pone.0104275
10.1016/0376-8716(96)01240-9
10.1097/ADM.0b013e3181e6ad48
10.15585/mmwr.mm6526a2
10.1016/j.drugpo.2012.10.003
10.1136/bmj.j1550
10.1016/j.jsat.2021.108276
10.1037/cou0000203
10.3389/fsoc.2021.619677
10.2307/799624
10.1146/annurev.soc.22.1.29
10.1016/j.drugalcdep.2009.05.021
10.1001/jama.2015.10345
10.1007/s10461-020-02887-1
10.1515/9780804764025
10.1080/08964289.2019.1619511
10.1016/j.jsat.2020.108223
10.1186/s12910-016-0108-2
10.1146/annurev.so.18.080192.001233
ContentType Journal Article
Copyright 2021. The Author(s).
COPYRIGHT 2021 BioMed Central Ltd.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2021
Copyright_xml – notice: 2021. The Author(s).
– notice: COPYRIGHT 2021 BioMed Central Ltd.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2021
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
ATCPS
AZQEC
BENPR
BHPHI
CCPQU
COVID
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
M0S
M1P
PATMY
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
PYCSY
7X8
5PM
DOA
DOI 10.1186/s12954-021-00535-y
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
ProQuest Health & Medical Collection (NC LIVE)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
Agricultural & Environmental Science Collection (ProQuest)
ProQuest Central Essentials
ProQuest Central
Natural Science Collection
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Environmental Science Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Environmental Science Collection
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Open Access Full Text
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Agricultural & Environmental Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Environmental Science Collection
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Environmental Science Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic

Publicly Available Content Database
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Social Welfare & Social Work
Public Health
EISSN 1477-7517
EndPage 10
ExternalDocumentID oai_doaj_org_article_9071dda301f94056a856d00602b83d5a
PMC8364307
A672304981
34391436
10_1186_s12954_021_00535_y
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GeographicLocations United States
United States--US
New York City New York
GeographicLocations_xml – name: United States
– name: New York City New York
– name: United States--US
GrantInformation_xml – fundername: NIDA NIH HHS
  grantid: R01 DA041298
– fundername: NIDA NIH HHS
  grantid: R01 DA041501
– fundername: NIDA NIH HHS
  grantid: P30 DA011041
– fundername: NIDA NIH HHS
  grantid: T32 DA007233
– fundername: NIDA NIH HHS
  grantid: K01 DA053159
– fundername: ;
– fundername: ;
  grantid: #5T32 DA007233-35; R01DA041298; R01DA041501
– fundername: ;
  grantid: NOH P30 DA011041
GroupedDBID ---
0R~
29I
2WC
2XV
53G
5GY
5VS
7X7
7XC
88E
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABIVO
ABUWG
ACGFO
ACGFS
ACHQT
ACIHN
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AEUYN
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
ATCPS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BHPHI
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
IAO
IHR
INH
INR
IPY
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PATMY
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
PYCSY
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PMFND
3V.
7XB
8FK
AZQEC
COVID
DWQXO
GNUQQ
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c563t-5e8f2dee296cebde0043922b722026b828d923c66d7460e5e54450f3089bcbc03
IEDL.DBID M48
ISSN 1477-7517
IngestDate Wed Aug 27 01:29:22 EDT 2025
Thu Aug 21 14:12:37 EDT 2025
Fri Jul 11 03:14:01 EDT 2025
Fri Jul 25 22:27:47 EDT 2025
Tue Jun 17 21:36:21 EDT 2025
Tue Jun 10 20:37:59 EDT 2025
Mon Jul 21 06:05:31 EDT 2025
Tue Jul 01 00:46:58 EDT 2025
Thu Apr 24 22:53:30 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Harm reduction
Methadone Maintenance Treatment (MMT)
Patients’ rights
Methadone clinics
Stigma
Take-home doses
Language English
License 2021. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c563t-5e8f2dee296cebde0043922b722026b828d923c66d7460e5e54450f3089bcbc03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-3304-3237
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12954-021-00535-y
PMID 34391436
PQID 2562633761
PQPubID 105462
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_9071dda301f94056a856d00602b83d5a
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8364307
proquest_miscellaneous_2561920181
proquest_journals_2562633761
gale_infotracmisc_A672304981
gale_infotracacademiconefile_A672304981
pubmed_primary_34391436
crossref_primary_10_1186_s12954_021_00535_y
crossref_citationtrail_10_1186_s12954_021_00535_y
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-08-14
PublicationDateYYYYMMDD 2021-08-14
PublicationDate_xml – month: 08
  year: 2021
  text: 2021-08-14
  day: 14
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Harm reduction journal
PublicationTitleAlternate Harm Reduct J
PublicationYear 2021
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References CB Fisher (535_CR30) 2008; 30
535_CR7
PP Pani (535_CR18) 1996; 41
PP Pani (535_CR19) 2000; 2
535_CR22
535_CR21
JK O’Donnell (535_CR52) 2017; 66
M Harris (535_CR47) 2013; 24
GR Gibbs (535_CR28) 2007; 703
B Saloner (535_CR8) 2015; 314
535_CR25
535_CR24
J Jaiswal (535_CR31) 2019; 45
KM Peavy (535_CR23) 2020; 24
R Daniulaityte (535_CR53) 2017; 66
535_CR33
H Keane (535_CR40) 2009; 20
J Gryczynski (535_CR45) 2013; 22
AY Walley (535_CR16) 2012; 6
I Etikan (535_CR26) 2016; 5
D Frank (535_CR43) 2020; 83
535_CR38
D Frank (535_CR9) 2018; 53
535_CR37
535_CR35
H Joseph (535_CR55) 2000; 67
E Peles (535_CR10) 2011; 5
AE Butler (535_CR27) 2018; 25
P Conrad (535_CR41) 1992; 18
ML DeVault (535_CR36) 1996; 22
P Conrad (535_CR42) 1975; 23
535_CR44
CA Latkin (535_CR51) 2019; 54
535_CR49
S Amiri (535_CR20) 2018; 93
R Cheng (535_CR12) 2009
CM Jones (535_CR50) 2016; 65
D Frank (535_CR29) 2021; 6
AJ Saxon (535_CR46) 1998; 6
D Frank (535_CR15) 2019; 3
535_CR11
B Moradi (535_CR34) 2017; 64
535_CR54
535_CR1
535_CR2
L Degenhardt (535_CR4) 2009; 105
535_CR3
535_CR5
D Eddie (535_CR13) 2019; 10
535_CR6
P Bourgois (535_CR39) 2000; 24
535_CR17
R Souleymanov (535_CR32) 2016; 17
535_CR14
TJ Cicero (535_CR48) 2005; 293
References_xml – volume: 22
  start-page: 285
  issue: 3
  year: 2013
  ident: 535_CR45
  publication-title: Am J Addict
  doi: 10.1111/j.1521-0391.2012.12004.x
– volume: 66
  start-page: 904
  issue: 34
  year: 2017
  ident: 535_CR53
  publication-title: MMWR Morb Mortal Wkly Rep
  doi: 10.15585/mmwr.mm6634a3
– ident: 535_CR35
– volume-title: Engaging people with lived experience for better health outcomes: collaboration with mental health and addiction service users in research, policy, and treatment
  year: 2009
  ident: 535_CR12
– volume: 53
  start-page: 311
  issue: 2
  year: 2018
  ident: 535_CR9
  publication-title: Subst Use Misuse
  doi: 10.1080/10826084.2017.1310247
– ident: 535_CR7
– volume: 10
  start-page: 1052
  year: 2019
  ident: 535_CR13
  publication-title: Front Psychol
  doi: 10.3389/fpsyg.2019.01052
– ident: 535_CR25
  doi: 10.1016/j.jsat.2020.108074
– volume: 24
  start-page: 165
  issue: 2
  year: 2000
  ident: 535_CR39
  publication-title: Cult Med Psychiatry
  doi: 10.1023/A:1005574918294
– volume: 67
  start-page: 347
  issue: 5–6
  year: 2000
  ident: 535_CR55
  publication-title: Mt Sinai J Med New York
– volume: 5
  start-page: 1
  issue: 1
  year: 2016
  ident: 535_CR26
  publication-title: Am J Theor Appl Stat
  doi: 10.11648/j.ajtas.20160501.11
– volume: 6
  start-page: 203
  issue: 3
  year: 1998
  ident: 535_CR46
  publication-title: Addict Res
  doi: 10.3109/16066359808993303
– volume: 703
  start-page: 38
  year: 2007
  ident: 535_CR28
  publication-title: Analyzing Qual Data
  doi: 10.4135/9781849208574.n4
– ident: 535_CR21
– volume: 25
  start-page: 561
  issue: 5
  year: 2018
  ident: 535_CR27
  publication-title: Collegian
  doi: 10.1016/j.colegn.2018.01.002
– ident: 535_CR44
– volume: 6
  start-page: 186
  issue: 3
  year: 2012
  ident: 535_CR16
  publication-title: J Addict Med
  doi: 10.1097/ADM.0b013e3182584772
– volume: 20
  start-page: 450
  issue: 5
  year: 2009
  ident: 535_CR40
  publication-title: Int J Drug Policy
  doi: 10.1016/j.drugpo.2008.10.005
– ident: 535_CR24
  doi: 10.1097/ADM.0000000000000685
– volume: 93
  start-page: 26
  year: 2018
  ident: 535_CR20
  publication-title: J Subst Abuse Treat
  doi: 10.1016/j.jsat.2018.07.006
– ident: 535_CR22
  doi: 10.1016/j.jsat.2021.108449
– volume: 66
  start-page: 1197
  issue: 43
  year: 2017
  ident: 535_CR52
  publication-title: MMWR Morb Mortal Wkly Rep
  doi: 10.15585/mmwr.mm6643e1
– volume: 83
  start-page: 102844
  year: 2020
  ident: 535_CR43
  publication-title: International Journal of Drug Policy.
  doi: 10.1016/j.drugpo.2020.102844
– volume: 54
  start-page: 998
  issue: 6
  year: 2019
  ident: 535_CR51
  publication-title: Subst Use Misuse
  doi: 10.1080/10826084.2018.1555597
– ident: 535_CR3
  doi: 10.2105/AJPH.2012.301049
– volume: 3
  start-page: 1
  issue: 2
  year: 2019
  ident: 535_CR15
  publication-title: J Extreme Anthropol
  doi: 10.5617/jea.6737
– ident: 535_CR38
– volume: 293
  start-page: 293
  issue: 3
  year: 2005
  ident: 535_CR48
  publication-title: JAMA
– ident: 535_CR54
  doi: 10.1371/journal.pone.0104275
– ident: 535_CR49
– volume: 41
  start-page: 81
  issue: 1
  year: 1996
  ident: 535_CR18
  publication-title: Drug Alcohol Depend
  doi: 10.1016/0376-8716(96)01240-9
– volume: 5
  start-page: 92
  issue: 2
  year: 2011
  ident: 535_CR10
  publication-title: J Addict Med
  doi: 10.1097/ADM.0b013e3181e6ad48
– volume: 65
  start-page: 667
  issue: 26
  year: 2016
  ident: 535_CR50
  publication-title: Morb Mortal Wkly Rep
  doi: 10.15585/mmwr.mm6526a2
– volume: 30
  start-page: 1
  issue: 3
  year: 2008
  ident: 535_CR30
  publication-title: IRB
– ident: 535_CR33
– volume: 24
  start-page: e43
  issue: 6
  year: 2013
  ident: 535_CR47
  publication-title: Int J Drug Policy
  doi: 10.1016/j.drugpo.2012.10.003
– ident: 535_CR1
  doi: 10.1136/bmj.j1550
– ident: 535_CR11
  doi: 10.1016/j.jsat.2021.108276
– ident: 535_CR14
– ident: 535_CR5
– volume: 64
  start-page: 500
  issue: 5
  year: 2017
  ident: 535_CR34
  publication-title: J Couns Psychol
  doi: 10.1037/cou0000203
– volume: 6
  start-page: 6
  year: 2021
  ident: 535_CR29
  publication-title: Front Sociol
  doi: 10.3389/fsoc.2021.619677
– volume: 2
  start-page: 33
  issue: 1
  year: 2000
  ident: 535_CR19
  publication-title: Heroin Addict Relat Clin Probl
– volume: 23
  start-page: 12
  issue: 1
  year: 1975
  ident: 535_CR42
  publication-title: Soc Probl
  doi: 10.2307/799624
– volume: 22
  start-page: 29
  issue: 1
  year: 1996
  ident: 535_CR36
  publication-title: Ann Rev Sociol
  doi: 10.1146/annurev.soc.22.1.29
– volume: 105
  start-page: 9
  issue: 1–2
  year: 2009
  ident: 535_CR4
  publication-title: Drug Alcohol Depend
  doi: 10.1016/j.drugalcdep.2009.05.021
– ident: 535_CR2
– volume: 314
  start-page: 1515
  issue: 14
  year: 2015
  ident: 535_CR8
  publication-title: JAMA
  doi: 10.1001/jama.2015.10345
– volume: 24
  start-page: 2469
  issue: 9
  year: 2020
  ident: 535_CR23
  publication-title: AIDS Behav
  doi: 10.1007/s10461-020-02887-1
– ident: 535_CR37
  doi: 10.1515/9780804764025
– volume: 45
  start-page: 79
  issue: 2
  year: 2019
  ident: 535_CR31
  publication-title: Behav Med
  doi: 10.1080/08964289.2019.1619511
– ident: 535_CR6
– ident: 535_CR17
  doi: 10.1016/j.jsat.2020.108223
– volume: 17
  start-page: 1
  issue: 1
  year: 2016
  ident: 535_CR32
  publication-title: BMC Med Ethics
  doi: 10.1186/s12910-016-0108-2
– volume: 18
  start-page: 209
  issue: 1
  year: 1992
  ident: 535_CR41
  publication-title: Ann Rev Sociol
  doi: 10.1146/annurev.so.18.080192.001233
SSID ssj0029538
Score 2.5657752
Snippet Methadone Maintenance Treatment (MMT) is widely recognized as one of the most effective ways of reducing risk of overdose, arrest, and transmission of...
Background Methadone Maintenance Treatment (MMT) is widely recognized as one of the most effective ways of reducing risk of overdose, arrest, and transmission...
Abstract Background Methadone Maintenance Treatment (MMT) is widely recognized as one of the most effective ways of reducing risk of overdose, arrest, and...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 88
SubjectTerms Clinics
Coronaviruses
COVID-19
Disease transmission
Dosage
Drug dosages
Drug use
Harm reduction
HIV
Human immunodeficiency virus
Humans
Maintenance
Marginalized groups
Medical research
Methadone
Methadone - therapeutic use
Methadone clinics
Methadone maintenance
Methadone Maintenance Treatment (MMT)
Methods
Narcotics
Opiate Substitution Treatment
Opioid-Related Disorders - drug therapy
Opioids
Overdose
Patient outcomes
Patient satisfaction
Patients
Patients’ rights
Policies
Policy
Public health
Retention
Risk management
Risk reduction
Stigma
Substance use
Take-home doses
Trauma
SummonAdditionalLinks – databaseName: DOAJ Open Access Full Text
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQnrgg3gS6yEiIh5C1iZM4DrcFsVqQyqkr9mbF9lit2k2gTVfaW8_8AlaCP9dfwjiPqhESXDg246R2Zsb-Jp75TMjzxGahEUYzk0c5S7SMWQFRxLi0NsOf0kS-OHn8WZyeJZ_O0_O9o758TlhLD9y-uCMM3iJrC7RDlyO4EIVMhfUsIhyfa9MGGuGa1wdTXaiVox_3JTJSHK0iv53FfDpCQ2jCrgbLUMPW_-ecvLcoDRMm91agk9vkVgcd6XHb5TvkBpR3yaitr6VfYOGKJdAXtL9QLef3yPft5ufHeru5XtHFbA50u_mxmH1bzyz1X8zN2rnVdvPrLUVroV1qB60crYs5sGl1AdRW_mMC9Wc54CyAwpKOoZ4WtiqBjgvPNuEpO4BO-ox1-mo8nrymHWErPv4a__oSVvfJ2cmHyftT1h2_wEwq4pqlIB23ADwXBrQFv2mYc64zzjFw0xiqWUSHRghUqgghBc_rE7o4lLk22oTxA3JQYmceEaqdQZjloEgcT2QOMgPBc5Np0FlhnQ1I1GtDmY6b3B-RsVBNjCKFajWoUIOq0aC6Csib3T1fW2aOv7Z-55W8a-lZtZsLaGuqszX1L1sLyEtvIsr7PnbPFF0JAw7Ss2ipY5E125YyCsho0BJ91gzFvZGpbs5YKQSfXMQ44aP42U7s7_R5cCVU66YNQnJPshaQh61N7oYU-yLqJBYByQbWOhjzUFLOpg2juIwRmIbZ4__xkp6Qm7xxNMmiZEQO6uUaDhG41fpp46O_AXvhQ0w
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Health & Medical Collection (NC LIVE)
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagXJAQgvIKLMhIiIdQ1MRJHIcLKoiqIC2nrejNSuwJu9olaTdZpN72zC-gEvy5_SXM5LFthNRjYjuxNQ-PxzPfMPYitLFnpMlck_iJG2YqcFPwfVcoa2N8VMan5OTxV3l4FH45jo47h1vVhVX2OrFR1LY05CPfw61ZyADFwX9_cupS1Si6Xe1KaFxnNwi6jLg6Pr44cCUozX2ijJJ7lU-XWi4FJTSwJu7ZYDNqMPv_18yXtqZh2OSlfejgDrvdGZB8v6X4XXYNil12q_W-8TapaJeN2qxb_g0WeboE_pL3L8rl_B77tVn_-Vxv1ucVX8zmwDfr34vZ6WpmOfnRzSrPq8367zuOPMS7gA9e5rxO5-BOyx_AbUkuBk4VHlA3YGPBx1BPU1sWwMcpYVAQkAfwSR_Hzl-Px5M3vINxxc-f469_QnWfHR18mnw8dLuiDK6JZFC7EahcWACRSAOZBbpKTITIYiHwOJfhAc6izWikRFJLDyIgtB8vDzyVZCYzXvCA7RQ4mUeMZ7lB4yuHNMxFqBJQMUiRmDiDLE5tbh3m99TRpkMsp8IZC92cXJTULUU1UlQ3FNVnDnu7HXPS4nVc2fsDEX3bk7C2mxfl8rvuRFcnaIVZm6ImzBM0b2WqImkJx0YgZ9soddgrYhlNGgGnZ9IusQEXSdhael_GzWWm8h02GvRESTbD5p7pdKdJKn3B9w57vm2mkRQdV0C5avqgoU7Qaw572PLodkkBpVaHgXRYPODewZqHLcVs2uCMqwDNVS9-fPW0nrCbohEp5frhiO3UyxU8RUOtzp410vgPEElA6Q
  priority: 102
  providerName: ProQuest
Title “It’s like ‘liquid handcuffs”: The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients’ lives
URI https://www.ncbi.nlm.nih.gov/pubmed/34391436
https://www.proquest.com/docview/2562633761
https://www.proquest.com/docview/2561920181
https://pubmed.ncbi.nlm.nih.gov/PMC8364307
https://doaj.org/article/9071dda301f94056a856d00602b83d5a
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELb2ceGCeBMolZEQD6FA4iS2g4RQF-1qWSkrBK3ozUpsh1YtCdumiN565hewEvy5_hLGblJtxIoTp6iZcRpnZuyxPfMNQo9CxTxJZebK2I_dMOOBm2rfdwlXisFPLn2TnJyc0uNBeDKMhjuoKXdUf8D5pUs7U09qMJu--H62fAMG_9oaPKcv5745rHJNsIGFK3GXu2gfZiZmKhok4fZUAbgC3iTOXNquNTlZDP-_R-oLU1U7jPLCvHR0DV2tHUrc22jAdbSjixuos8m6xZ_0NE9nGj_GzY1yNrmJfqxXv95V69X5HE_HE43Xq5_T8dlirLDZR5eLPJ-vV79fYdAhXAd84DLHVTrR7qj8orEqzRYDNhUeYGwAYoETXY1SVRYaJ6nBoDBAHhr3mzh2_DRJ-s9wDeMKjz-Hv_6m57fQ4Oiw__bYrYsyuDKiQeVGmudEaU1iKnWmtDlKjAnJGCGwnMtgAafAZ5SUgqippyNt0H68PPB4nMlMesFttFfAy9xFOMslOF-5TsOchDzWnGlKYskynbFU5cpBfiMNIWvEclM4YyrsyoVTsZGgAAkKK0GxdNDzbZuvG7yOf3IfGCFvOQ3Wtr1Rzj6L2nRFDF6YUimMhHkM7i1NeUSVwbEhoNkqSh30xKiIMDoKryfTOrEBOmmwtUSPMnuYyX0HdVqcYMmyTW6UTDSGIMAlJTSAaQDID7dk09JExxW6XFgecNQN9JqD7mx0ctulwKRWhwF1EGtpa6vPbUoxHlmccR6Au-qxe__jI91HV4g1NO76YQftVbOFfgDuXJV10S4bsi7a7_VOPp7A9eDw9P2Hrt0c6Vr7_QNe2VDP
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKOYCEEJRXoICReApFTZys4yAhVB7VlnZ72qq9mcSe0FWXTbsP0N72zC-gEvwFftT-Emby2DZC6q3HjZ2srXnbM98w9jS0kWekSV0T-7EbpipwE_B9VyhrI_ypjE_FyZ0d2d4NP--39pfY37oWhtIqa51YKGqbGzojX0PTLGSA4uC_Ozp2qWsU3a7WLTRKttiC6Q8M2UZvNz8ifZ8JsfGp-6HtVl0FXNOSwdhtgcqEBRCxNJBaoLuwWIg0EgLjkRQjEItOj5ES1yo9aAHB1XhZ4Kk4NanxAvzuJXYZDa9HwV60fxrgxag96sIcJddGPl2iuZQEUcCouNOG8St6BPxvCc6Ywmaa5hm7t3GDXa8cVr5ecthNtgSDFXatPO3jZRHTClstq3z5HvSzZAj8Oa8f5MPDW-znfPZ7czyfnYx4v3cIfD771e8dT3qW07m9mWTZaD7784Yjz_IqwYTnGR8nh-Ae5N-A25yONDh1lEBdhIMD3oHxQWLzAfBOQpgXBBwCvFvnzfOXnU73Fa9gY_HzJ_jX32F0m-1eCLnusOUBLuYe42lm0NnLIAkzEaoYVARSxCZKIY0Sm1mH-TV1tKkQ0qlRR18XkZKSuqSoRorqgqJ66rDXi3eOSnyQc2e_J6IvZhK2d_EgH37VlarQMXp91iaoebMY3WmZqJa0hJsjUJJsK3HYC2IZTRoIl2eSqpACN0lYXnpdRsXlqfIdttqYiZrDNIdrptOV5hrpUzlz2JPFML1J2XgDyCfFHAwMCOrNYXdLHl1sKaBS7jCQDosa3NvYc3Nk0DsocM1VgO6xF90_f1mP2ZV2t7Ottzd3th6wq6IQL-X64SpbHg8n8BCdxHH6qJBMzr5ctCr4B9qbfMo
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E2%80%9CIt%E2%80%99s+like+%E2%80%98liquid+handcuffs%E2%80%9D%3A+The+effects+of+take-home+dosing+policies+on+Methadone+Maintenance+Treatment+%28MMT%29+patients%E2%80%99+lives&rft.jtitle=Harm+reduction+journal&rft.au=David+Frank&rft.au=Pedro+Mateu-Gelabert&rft.au=David+C.+Perlman&rft.au=Suzan+M.+Walters&rft.date=2021-08-14&rft.pub=BMC&rft.eissn=1477-7517&rft.volume=18&rft.issue=1&rft.spage=1&rft.epage=10&rft_id=info:doi/10.1186%2Fs12954-021-00535-y&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_9071dda301f94056a856d00602b83d5a
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-7517&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-7517&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-7517&client=summon